July 15, 2014 — Sun Nuclear Corp. announced its intended acquisition of Gammex Inc., which became effective July 2. The acquisition combines two complementary product lines within the radiation oncology marketplace, and adds diagnostic radiology quality assurance (QA) capability to Sun Nuclear's therapeutic radiation oncology QA and dosimetry position.
"I am excited to see these two companies combine because of their deep synergies," said Margaret Lescrenier, president of Gammex Inc. "We started Gammex in 1969 and have been pioneers in radiation oncology and diagnostic products for over 40 years. We see a promising future for continued innovation and growth of the Gammex product line under the new leadership of SNC."
"We are very excited to bring Gammex into the Sun Nuclear family," says Jeff Simon, CEO of Sun Nuclear. "Gammex has a long history of meaningful innovation and technical expertise that fits perfectly with Sun Nuclear's core values and mission. We believe Gammex is a company of great opportunity, and look forward to providing the market leadership in quality assurance and patient safety that Sun Nuclear is known for today, and to continue Gammex's rich history of innovation. We are also excited to make this investment in Middleton (Madison) Wisconsin, a recognized world leader in the medical physics and cancer care industry, and home to the University of Wisconsin."